The Russia Direct Investment (RDIF) is currently guiding Russia’s Sputnik V trial vaccine, reaching the Phase 3 trials. RDIF has collaborated with the Hyderabad, India – based Dr.Reddy’s Laboratories to undergo trials, to seek regulatory approval and supply 100 million doses of the COVID-19 vaccine.
“We are pleased to partner with RDIF to bring the vaccine to India. The Phase 1 and 2 results have shown promise, and will be conducting Phase 3 trials in India,” said G.V Prasad, co-chairman and managing Director, Dr. Reddy Laboratories on RDIF.
First registered vaccine for COVID-19
On August 11, the Sputnik V vaccine, produced by the Gamaleya National Research Institute of Epidemiology and Microbiology was registered by the Ministry of Health of Russia. It emerged as the world’s first recorded vaccine in opposition to COVID-19.
Trials and results
According to The Lancet (a well-known international medical journal), a research paper stated the results of Phase I and Phase II trials of the vaccine on September 4, 2020. The results visualized no serious effects and a steady immune response in 100% of the vaccine trial part takers. Presently, 40,000 volunteers are ongoing clinical trials. More than 55,000 have applied for the same. The first report is said to be released in October- November.
On the contrary, one in seven volunteers have complained of weakness, muscle pain for a day and an occasional increase in body temperature.
Components of Sputnik V vaccine
Gam – COVID –Vac or Sputnik V vaccine, is a COVID-19 vaccine trial produced by Russian health and research institute Gamaleya. It is a viral two sector vaccine centered on the human adenovirus (a common cold virus). The vaccine is merged with the spike protein of SARS-CoV-2 to brace an immune response. Two recombinants namely adenovirus type-5(Ad5) and adenovirus type-26 (Ad 26) are used as agents in the vaccine. The Ad 26 vaccine is used on day 1 and Ad 5 is used on Day 21 to uplift the response.
Liberation of the vaccine
For now, the vaccine is under Phase 3 trials and after the regulatory approvals in India it is estimated to supply 100 million doses of vaccine. Delivery of the Sputnik-V vaccine will go on the floors by late 2020, after the completion of all the trials and registration process in India.